Pertussis, a highly contagious disease of the respiratory tract, is caused by exposure to bacteria (Bordetella pertussis) found in the mouth, nose and throat of an infected person. Pertussis is primarily spread by direct contact with discharge from the nose or throat of infected individuals. Classic - or severe pertussis - as defined by the World Health Organization, consists of at least 21 days of cough illness (with the cough coming in spasms or paroxysms), associated whoops or post-cough vomiting, and laboratory confirmation. Despite widespread vaccination, reports of pertussis continue to rise in the U.S. At particular risk are newborns and babies who have not yet been fully vaccinated against pertussis, who are more likely to have severe pertussis, and who face the possibility of serious complications and death. Over the last decade, 80% of pertussis deaths have occurred in infants under 6 months of age.
A vaccine to protect adults and adolescents against illness due to Bordetella pertussis infection--or whooping cough--has proved more than 90 percent effective in a national, large-scale clinical study, according to research results published in this week's issue of The New England Journal of Medicine.
A Cornell University virologist has isolated a highly contagious equine flu virus that is spreading a sometimes-fatal respiratory flu among dogs, and is responsible for a major dog-flu outbreak in New York state. There is no evidence that the virus could infect people.
These results show that a natural product of vitamin A can have an important role in regulating immunity and, when administered along with PIC, might be a potentially powerful nutritional-immunological assist in vaccination."
New research does not support a belief that children receiving multiple vaccines increase their risk of hospitalization for a nontargeted infectious disease, according to a study in the August 10 issue of JAMA: The Journal of the American Medical Association.
According to U.S. health officials, a record high rate of 81 percent of toddlers 19 months to 3 years old are now getting vaccinated with the full recommended series.
The adolescent birth rate has reached another record low, the death rate for children between ages 1 and 4 is the lowest ever, young children are more likely to receive their recommended immunizations, and fourth graders are scoring better in math, according to a yearly compendium of statistics from federal agencies concerned with children.
Parents often wonder why it takes a year or more and multiple shots to fully immunize their children against diseases like diphtheria and pertussis.
The U.S. Food and Drug Administration (FDA) has given drug company Sanofi-Aventis approval to sell Adacel, a vaccine against whooping cough for people ages 11 to 64.
Hoping to prevent ear infections for the more than 15 million children in the United States who suffer from them, a promising new vaccine candidate to prevent middle ear infections (otitis media) is being developed by researchers at the Columbus Children’s Research Institute (CCRI) on the campus of Columbus Children’s Hospital.
Despite childhood vaccination rates at all-time highs, pertussis (whooping cough) has re-emerged over the past two decades, especially among adolescents, adults, and young infants. Because of this resurgence, federal health policymakers are considering a national booster vaccination program.
The Journal of the American Medical Association (JAMA) has announced that a study to be published in the June 22/29 issue found that a new vaccine against whooping cough is effective in teens and adults, carriers of the contagious respiratory disease so dangerous to infants.
A new combination vaccine not yet on the market appears to provide a booster for immunity against tetanus, diphtheria, and pertussis for adolescents and adults and was found to have a similar overall safety profile when compared to the current licensed tetanus-diphtheria vaccine, according to a new study in JAMA.
A comprehensive system of vaccine development in the U.S. resulted in a reduction of 87 to more than 99 percent in illness from ten vaccine-preventable diseases during the twentieth century. These dramatic successes should not be taken for granted, however, as the vaccine system now faces numerous challenges in manufacturing and development, according to a review article in the May/June issue of Health Affairs.
Recent shortages of vaccines, most recently the flu vaccine during the past winter, are not short-term glitches--they reflect long-term problems in the vaccine industry. A variety of social, legal and economic forces have caused pharmaceutical companies to withdraw their commitment to vaccines, according to pediatrician and vaccine expert Paul A. Offit, M.D., chief of Infectious Diseases at The Children's Hospital of Philadelphia.
GlaxoSmithKline today announced that its booster vaccine, Boostrix received approval from the United States (U.S.) Food and Drug Administration (FDA).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
In recognition of National Infant Immunization Week (April 24, 2005 through April 30, 2005), the Nassau County Department of Health urges all parents to ensure that their infants and toddlers are fully protected from the following vaccine preventable diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, measles, mumps, rubella, hepatitis B, haemophilus influenza (meningitis), varicella (chickenpox), pneumococcal disease and influenza.
Global health leaders today presented new research showing that vaccinating infants against Streptococcus pneumoniae -- a bacterium that causes deadly pneumonia, meningitis and sepsis -- could substantially reduce death and serious illness among children in the developing world. If used widely, a pneumococcal conjugate vaccine could prevent hundreds of thousands of child deaths each year.
A vaccine against pneumonia and invasive pneumococcal disease, a severe form of bacterial infection, can substantially reduce hospital admissions and improve the survival of children in developing countries, concludes a trial published in this week’s issue of The Lancet.
The U.S. Food and Drug Administration (FDA) is recommending the development of a vaccine to prevent the occurrence of pertussis (Whooping Cough) in adolescents.